Wolverine Asset Management’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-520,184
Closed -$5.17M 2208
2021
Q3
$5.17M Sell
520,184
-544
-0.1% -$5.4K 0.04% 278
2021
Q2
$5.18M Sell
520,728
-9,546
-2% -$96.1K 0.04% 269
2021
Q1
$5.28M Sell
530,274
-28,426
-5% -$303K 0.04% 235
2020
Q4
$6.03M Buy
558,700
+86,398
+18% +$889K 0.04% 237
2020
Q3
$4.9M Buy
472,302
+395,577
+516% +$4.11M 0.04% 228
2020
Q2
$771K Buy
+76,725
New +$763K 0.01% 608

Other funds holding STLN

Wolverine Asset Management's STLN Position: Q4 2021 in Review

Wolverine Asset Management sold out of Starling Oncology Institute, Inc. Common Stock (STLN) in Q4 2021, closing a stake of 520,184 shares — an estimated $5.17M sold.

Wolverine Asset Management first reported a position in STLN in Q2 2020 and held it in 6 quarters. The position peaked at $6.03M in Q4 2020. 21 funds tracked by Wall St. Rank hold STLN as of Q4 2021.

  • Wolverine Asset Management reported no remaining Starling Oncology Institute, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Wolverine Asset Management sold 520,184 Starling Oncology Institute, Inc. Common Stock shares in Q4 2021, an estimated $5.17M.
  • Wolverine Asset Management first reported a position in Starling Oncology Institute, Inc. Common Stock in Q2 2020 and held it in 6 quarters.
  • Wolverine Asset Management's Starling Oncology Institute, Inc. Common Stock position peaked at $6.03M in Q4 2020.
  • 21 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q4 2021.

Based on Wolverine Asset Management's 13F filing for Q4 2021, filed 9 Feb 2022.